首页>
外国专利>
DSRNA/LYMPHOKINE THERAPY OPTIONALLY USING CYCLOOXYGENASE ACTIVATOR TO INCREASE THE LEVELS OF NK (NATURAL KILLER) AND LAK (LYMPHOKINE ACTIVATED KILLER) CELLS
DSRNA/LYMPHOKINE THERAPY OPTIONALLY USING CYCLOOXYGENASE ACTIVATOR TO INCREASE THE LEVELS OF NK (NATURAL KILLER) AND LAK (LYMPHOKINE ACTIVATED KILLER) CELLS
The unexpected synergistic interplay between lymphokines and dsRNAs which dramatically reduces the necessary dosages of lymphokines, especially IL-2, and simultaneously widens their therapeutic range in the treatment of various types of cancers, viral disorders or other body conditions characterized by disregulated immune states (e.g., autoimmune diseases). Specific combinations of dsRNA plus IL-2 significantly increase survival in human melanoma-bearing animals in part because of augmentation by dsRNA of lymphokine activated killer cells (LAK) which are first formed in response to IL-2 exposure. The invention has wide applicability to non-toxic, efficacious control of both human cancer and various human viral infections and immunoregulatory disorders.
展开▼